BioCentury | Jan 13, 2014
Company News

Astellas, Immuno-Biological Laboratories deal

...medicines. The companies could not be reached for details. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Immuno-Biological Laboratories Co. Ltd....
BioCentury | Dec 18, 2008
Targets & Mechanisms

Tyrosine kinase inhibitors for diabetes

Since the kinase inhibitors Gleevec imatinib from Novartis AG and Sutent sunitinib from Pfizer Inc. were approved to treat various cancer indications, academics have been looking to take advantage of the off-target promiscuity of these...
BioCentury | Feb 19, 2007
Strategy

Intellect's new frame of mind

...its clearance from the brain. Last month, Intellect licensed a pair of humanized MAbs from Immuno-Biological Laboratories Co. Ltd....
BioCentury | Jan 15, 2007
Company News

Immuno-Biological Laboratories, Intellect Neurosciences deal

...use and sell related murine MAbs for research and diagnostic purposes. Further terms were undisclosed. Immuno-Biological Laboratories Co. Ltd....
BioCentury | Jan 1, 2007
Company News

IBL Gesellschaft fuer Immunchemie und Immunbiologie mbH, Immuno-Biological Laboratories, Innogenetics sales and marketing update

...Financial terms were not disclosed. IBL Gesellschaft fuer Immunchemie und Immunbiologie mbH , Hamburg, Germany Immuno-Biological Laboratories Co. Ltd....
BioCentury | Jun 26, 2006
Company News

Crucell, Immuno-Biological Laboratories deal

...receive a license fee and annual maintenance fees. Crucell N.V. (Euronext:CRXL; CRXL), Leiden, the Netherlands Immuno-Biological Laboratories Co. Ltd....
BioCentury | May 1, 2006
Company News

Immuno-Biological Laboratories, Innogenetics NV, Takeda deal

...Takeda, which granted INNX sublicensing rights under a 2004 deal (see BioCentury, June 14, 2004). Immuno-Biological Laboratories Co. Ltd....
Items per page:
1 - 7 of 7
BioCentury | Jan 13, 2014
Company News

Astellas, Immuno-Biological Laboratories deal

...medicines. The companies could not be reached for details. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Immuno-Biological Laboratories Co. Ltd....
BioCentury | Dec 18, 2008
Targets & Mechanisms

Tyrosine kinase inhibitors for diabetes

Since the kinase inhibitors Gleevec imatinib from Novartis AG and Sutent sunitinib from Pfizer Inc. were approved to treat various cancer indications, academics have been looking to take advantage of the off-target promiscuity of these...
BioCentury | Feb 19, 2007
Strategy

Intellect's new frame of mind

...its clearance from the brain. Last month, Intellect licensed a pair of humanized MAbs from Immuno-Biological Laboratories Co. Ltd....
BioCentury | Jan 15, 2007
Company News

Immuno-Biological Laboratories, Intellect Neurosciences deal

...use and sell related murine MAbs for research and diagnostic purposes. Further terms were undisclosed. Immuno-Biological Laboratories Co. Ltd....
BioCentury | Jan 1, 2007
Company News

IBL Gesellschaft fuer Immunchemie und Immunbiologie mbH, Immuno-Biological Laboratories, Innogenetics sales and marketing update

...Financial terms were not disclosed. IBL Gesellschaft fuer Immunchemie und Immunbiologie mbH , Hamburg, Germany Immuno-Biological Laboratories Co. Ltd....
BioCentury | Jun 26, 2006
Company News

Crucell, Immuno-Biological Laboratories deal

...receive a license fee and annual maintenance fees. Crucell N.V. (Euronext:CRXL; CRXL), Leiden, the Netherlands Immuno-Biological Laboratories Co. Ltd....
BioCentury | May 1, 2006
Company News

Immuno-Biological Laboratories, Innogenetics NV, Takeda deal

...Takeda, which granted INNX sublicensing rights under a 2004 deal (see BioCentury, June 14, 2004). Immuno-Biological Laboratories Co. Ltd....
Items per page:
1 - 7 of 7